Expression of Cdc42 in tongue squamous cell carcinoma and its clinical significance

doi:10.19438/j.cjoms.2018.03.008

Abstract

Abstract: PURPOSE: To investigate expression of cell division cycle 42 (Cdc42) and its clinical significance in tongue squamous cell carcinoma (TSCC). METHODS: Forty-two patients with TSCC were collected and the expression of Cdc42 in tumor, adjacent tissue and normal tissue was detected by immunohistochemistry and Western blot, respectively. The correlation of Cdc42 expression and clinical parameter were analyzed as well. Statistical analysis was performed using t test and rank sum test with SPSS 13.0 software package. RESULTS: The positive rate of Cdc42 in TSCC and adjacent tissue was 80.95% and 52.38%, respectively, which was higher than 11.90% in normal tissue. There was significant difference of Cdc42 expression between tumor, adjacent tissue and normal tissue (P<0.05). Cdc42 protein expression in cases with cervical lymph node metastasis was significantly higher than in cases without cervical lymph node metastasis (P<0.05). The expression of Cdc42 in TSCC had positive relation with clinical stages (P<0.05), but no correlation with pathological grade, age and gender (P>0.05). The expression levels of Cdc42 in nucleus were associated with pathological grade of TSCC. CONCLUSIONS: The results indicated Cdc42 positive expression is higher in TSCC and adjacent tissue. Over-expression of Cdc42 may play an important role in TSCC development and progress.

Key words: Tongue, Squamous cell carcinoma, Cdc42

CLC Number:

R739.86

LIAO Yi-xiang, KONG Qing-nuan, GUO Qing-yuan, HE Zong-xuan, QIU Jing, CHEN Zheng-gang.. Expression of Cdc42 in tongue squamous cell carcinoma and its clinical significance[J]. China Journal of Oral and Maxillofacial Surgery, 2018, 16(3): 231-236.

References

[1] 郑家伟, 李金忠, 钟来平, 等. 口腔鳞状细胞癌临床流行病学研究现状 [J]. 中国口腔颌面外科杂志, 2007, 5(2): 83-90.
[2] Palasz P, Adamski L, Górska-Chrzastek M, et al. Contemporary diagnostic imaging of oral squamous cell carcinoma-a review of literature [J]. Pol J Radiol, 2017, 82: 193-202.
[3] Rusthoven K, Ballonof A, Raben D, et al. Poor prognosis in patients with stage Ⅰ and Ⅱ oral tongue squamous cell carcinoma [J]. Cancer, 2008, 112(2): 345-351.
[4] Rothenberg SM, Ellisen LW. The molecular pathogenesis of head and neck squamous cell carcinoma[J]. J Clin Invest, 2012, 122(6): 1951-1957.
[5] Fernández-Medarde A, Santos E. Ras in cancer and developmental diseases [J]. Genes Cancer, 2011, 2(3): 344-358.
[6] Gao J, Long B, Wang Z. Role of Notch signaling pathway in pancreatic cancer [J].Am J Cancer Res, 2017, 7(2): 173-186.
[7] Sinha S, Yang W. Cellular signaling for activation of Rho GTPase Cdc42 [J]. Cell Signal, 2008, 20(11): 1927-1934.
[8] Erickson JW, Cerione RA. Multiple roles for Cdc42 in cell regulation [J]. Curr Opin Cell Biol, 2001, 13(2): 153-157.
[9] Jaffe AB, Kaji N, Durgan J, et al. Cdc42 controls spindle orientation to position the apical surface during epithelial morphogenesis [J]. J Cell Biol, 2008, 183(4): 625-633.
[10] Arias-Romero LE, Chernoff J. Targeting Cdc42 in cancer [J]. Expert Opin Ther Targets, 2013, 17(11): 1263-1273.
[11] 张同韩, 刘海潮, 梁玉洁, 等. Notch信号通路分子在舌鳞癌中的表达及意义 [J].华西口腔医学杂志, 2013, 31(3): 303-309.
[12] 邢传平, 刘斌, 董亮. 免疫组织化学标记结果的判断方法 [J]. 中华病理学杂志, 2001, 30(4): 318.
[13] 李江. 口腔癌的临床病理特征与预后 [J]. 中国口腔颌面外科杂志, 2008, 6(1): 17-21.
[14] Lin Y, Zheng Y. Approaches of targeting Rho GTPases in cancer drug discovery [J]. Expert Opin Drug Discov, 2015, 10(9): 991-1010.
[15] 陈正岗, 唐永平, 童磊, 等. 体外RNA干扰RhoA基因对舌癌细胞侵袭的影响 [J]. 华西口腔医学杂志, 2016, 34(2): 183-188.
[16] Wu X, Quondamatteo F, Brakebusch C. Cdc42 expression in keratinocytes is required for the maintenance of the basement membrane in skin [J]. Matrix Biol, 2006, 25(8): 466-474.
[17] Troester MA, Lee MH, Carter M, et al. Activation of host wound responses in breast cancer microenvironment [J]. Clin Cancer Res, 2009, 15(22): 7020-7028.
[18] Castven D, Fischer M, Becker D, et al. Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas[J]. Oncotarget, 2017, 8(30): 48688-48700.
[19] Trujillo KA, Heaphy CM, Mai M, et al. Markers of fibrosis and epithelial to mesenchymal transition demonstrate field cancerization in histologically normal tissue adjacent to breast tumors [J]. Int J Cancer, 2011, 129(6): 1310-1321.
[20] Meriane M, Charrasse S, Comunale F, et al. Participation of small GTPases Rac1 and Cdc42Hs in myoblast transformation [J]. Oncogene, 2002, 21(18): 2901-2907.
[21] Qadir MI, Parveen A, Ali M. Cdc42: Role in cancer management [J]. Chem Biol Drug Des, 2015, 86(4): 432-439.
[22] Warner SJ, Yashiro H, Longmore GD. The Cdc42/Par6/aPKC polarity complex regulates apoptosis-induced compensatory proliferation in epithelia [J]. Curr Biol, 2010, 20(8): 677-686.
[23] Yamaguchi H, Lorenz M, Kempiak S, et al. Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin [J]. J Cell Biol, 2005, 168(3): 441-452.
[24] Tsai CH, Chiu JH, Yang CW, et al. Molecular characteristics of recurrent triple-negative breast cancer [J]. Mol Med Rep, 2015, 12(5): 7326-7334.
[25] Chrysanthou E, Gorringe KL, Joseph C, et al. Phenotypic characterisation of breast cancer: the role of CDC42[J]. Breast Cancer Res Treat, 2017, 164(2): 317-325.
[26] Stengel K, Zheng Y. Cdc42 in oncogenic transformation, invasion, and tumorigenesis [J]. Cell Signal, 2011, 23(9): 1415-1423.
[27] Ma D, Cheng Y, Zhang Y, et al. Expression of CDC42 in cervical squamous cell carcinoma and its correlation with clinicopathologic characteristics [J]. Chin J Cancer Res, 2013, 25(6): 656-661.
[28] Halon A, Donizy P, Surowiak P, et al. ERM/Rho protein expression in ductal breast cancer: a 15 year follow-up[J]. Cell Oncol (Dordr), 2013, 36(3): 181-190.